Maravai Lifesciences Holdings, Inc. (MRVI): Cash & Equivalents
$216.89M
As of 2025-12-31
$70.09M
As of 2026-06-30
-30.0%
3-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $216.89M | -32.7% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $322.40M | n/a | 2026-02-26, Balance as of period end |
| 2024-09-30 | $578.16M | n/a | 2025-03-18, Balance as of period end |
| 2024-06-30 | $573.17M | n/a | 2025-03-18, Balance as of period end |
| 2023-12-31 | $574.96M | -9.0% | 2025-03-18, Balance as of period end |
| 2022-12-31 | $632.14M | n/a | 2024-02-29, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Maravai Lifesciences Holdings, Inc. (MRVI) | 2025-12-31 | $216.89M | -32.7% |
| Stoke Therapeutics, Inc. (STOK) | 2025-12-31 | $84.22M | -34.2% |
| Lifevantage Corp (LFVN) | 2025-06-30 | $20.20M | +19.6% |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | $54.30M | -39.1% |
| Cryoport, Inc. (CYRX) | 2025-12-31 | $250.49M | +633.8% |
| Phathom Pharmaceuticals, Inc. (PHAT) | 2025-12-31 | $129.97M | -56.3% |
| Syndax Pharmaceuticals Inc (SNDX) | 2025-12-31 | $134.93M | -12.4% |
| Amarin Corp PLC (AMRN) | 2025-12-31 | $134.66M | +11.3% |
| Vanda Pharmaceuticals Inc. (VNDA) | 2025-12-31 | $84.85M | -17.1% |
Compare MRVI, STOK, LFVN, RYTM side by side · Screen every company in Pharmaceutical Preparations ↗